Teresa Brophy Bair - 27 Sep 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Legal Officer
Signature
Thomas Doyle, Attorney-in-fact for Teresa Bair
Issuer symbol
KURA
Transactions as of
27 Sep 2025
Net transactions value
-$78,736
Form type
4
Filing time
29 Sep 2025, 19:30:08 UTC
Previous filing
19 May 2025
Next filing
14 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bair Teresa Brophy Chief Legal Officer C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO Thomas Doyle, Attorney-in-fact for Teresa Bair 29 Sep 2025 0001813058

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +48,900 +45% $0.000000 156,848 27 Sep 2025 Direct
transaction KURA Common Stock Sale $78,736 -8,805 -5.6% $8.94 148,043 29 Sep 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on September 27, 2025, resulting in the vesting of 1/6th of the underlying shares.